Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Liminal BioSciences Inc. LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Post by barcodewhizon Sep 30, 2005 5:37pm
391 Views
Post# 9639313

Hemosol

HemosolI have been buying HMSL shares for the last few days, I am building a decent position. While there's no question there's risk in the stock, I think the underlying value is undeniable, especially when you add the intellectual value of the Cascade process agreement with Prometic. Here's my call, bridge financing for this company is a DONE DEAL.... there will be a very significant JV announcement shortly as per the innuendo's of both Prometic and Hemosol's recent news releases. Any kind of JV or takeover of this magnitude takes time. EVEN NET OF DEBT.....The plant and equipment of HEMOSOL are worth 4 times the current market cap of the company and that DOESNT include the COMPETITION ENTERPRISE VALUE that this package represents to one existing COHN Fractionator vs another. The bottom line is this, the fractionator that moves on this package and puts together a joint deal with HML and PLI is going to have a HUGE and IMMEDIATE competitive advantage over all the other fractionators worldwide.... ANY DEAL HEMOSOL PUTS TOGETHER WILL BE GREAT FOR PROMETIC
Bullboard Posts

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse